XML 50 R41.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies (Details)
1 Months Ended 3 Months Ended
Jan. 05, 2021
Nov. 01, 2020
USD ($)
Nov. 01, 2020
EUR (€)
Dec. 31, 2021
shares
Apr. 17, 2021
Feb. 26, 2021
USD ($)
Jul. 31, 2020
USD ($)
Mar. 31, 2021
USD ($)
shares
Commitments and Contingencies (Details) [Line Items]                
Employment agreement, description         the CEO was granted 7,630,949 vested shares of the Company’s common stock in April 2020, and the CEO’s base salary was increased to $120,000. In addition, the CEO shall be eligible to earn a bonus, subject to the sole discretion of the Company’s Board. On January 18, 2021, the Company entered into an amendment (the “Amendment”) to the Employment Agreement, effective as of January 1, 2021, pursuant to which the CEO’s base salary was increased from $120,000 per year to $180,000 per year.      
License fee           $ 10,000 $ 10,000  
License agreement, description               the Company shall pay UMB (i) a license fee (ii) certain event-based milestone payments, (iii) royalty payments depending on net revenues, and (iv) a tiered percentage of sublicense income. The Company shall pay to UMB a license fee of $75,000, payable as follows: (a) $25,000 shall be due within 30 days following the Master License Agreement Effective Date; and (b) $50,000 on or before the first anniversary of the Master License Agreement Effective Date. The license fee is non-refundable, and is not creditable against any other fee, royalty, or payment. The Company shall be responsible for payment of all patent expenses in connection with preparing, filing, prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid the $25,000 license fee on February 17, 2021 and was recorded in prepaid expenses to be amortized over the 15-year term. The Company recognized amortization expense of $625 during the three months ended March 31, 2021. At March 31, 2021, prepaid expense and other current assets – current amounted $5,000 and prepaid expenses – non-current amounts $19,375 as reflected in the accompanying condensed consolidated balance sheets.
Royalty payments, description               the Company agreed to pay certain royalty payments as follows: (i)3% on sales of Licensed Products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000; and (ii)5% on sales of Licensed Products during the applicable calendar year for sales greater than $50,000,000; and Furthermore, the Company agreed to pay UMB minimum royalty payments, as follows:
Sublicense income, description               (a) 25% of sublicense income which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first licensed product; and (b) 15% of sublicense income which is receivable with respect to any sublicense that is executed after the filing of an NDA (or foreign equivalent) for the first licensed product.
Commercial sale term               10 years
License agreement expire               15 years
Total fee   $ 507,602 € 433,885          
Amortization expense               $ 39,549
Sponsored study agreement, description The total cost under the Sponsored Study Agreement shall not exceed $81,474 which is payable in two equal installments of $40,737 upon execution of the Sponsored Study Agreement and $40,737 upon completion of the project with an estimated project timeline of nine months. The Company paid $40,737 on January 13, 2021 which was recorded in prepaid expense to be amortized over the nine-month period. The Company recognized amortization expense of $9,053 during the three months ended March 31, 2021.              
Non-refundable cash payment               $ 500,000
Net sale percentage               2.00%
Licensor share (in Shares) | shares               500
Aggregate of converted shares (in Shares) | shares               625,000
Reverse stock split vote, description               (i) the date that the Reverse Stock Split Vote is approved by AIkido’s stockholders and (ii) December 31, 2021, at the option of the holder, into such number of shares of AIkido’s common stock determined by dividing the Stated Value by the Conversion Price. “Stated Value” means $1,000. “Conversion Price” means $0.80, subject to adjustment. The Company valued the 500 Series M Convertible Preferred stock which is equivalent into AIkido’s 625,000 shares of common stock at a fair value of $0.85 per common share or $531,250 based quoted trading price of AIkido’s common stock on the date of grant. The Company recorded an equity investment of $531,250 (see Note 3) and deferred revenue of $531,250 to be recognized as revenues over the term of the license.
Deferred revenue               $ 1,031,250
Revenue term               15
Recognized revenues               $ 17,188
Deferred revenue – current portion               68,750
Deferred revenue – long-term portion               $ 945,312
Consideration fee payable percentage               110.00%
Forecast [Member]                
Commitments and Contingencies (Details) [Line Items]                
Number of voting shares (in Shares) | shares       20,000